Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients

A major complication in treating hemophilia A is the development of neutralizing antibodies (inhibitors) against therapeutic administered factor VIII (FVIII), which occurs in approximately 20-30% of patients with severe disease. These inhibitors render FVIII replacement therapy ineffective and incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalilian, Sheyda, Motovali-Bashi, Majid, Rezaie, Halimeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Babol University of Medical Sciences 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422849/
https://www.ncbi.nlm.nih.gov/pubmed/32832483
http://dx.doi.org/10.22088/IJMCM.BUMS.9.1.33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422849/
https://www.ncbi.nlm.nih.gov/pubmed/32832483
http://dx.doi.org/10.22088/IJMCM.BUMS.9.1.33

Ejemplares similares